Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 2
2011 1
2012 1
2014 1
2015 3
2017 1
2019 2
2020 2
2021 3
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.
Iinuma K, Yamada T, Kameyama K, Taniguchi T, Kawada K, Ishida T, Nagai S, Enomoto T, Ueda S, Takagi K, Kawase M, Takeuchi S, Kawase K, Kato D, Takai M, Nakane K, Koie T. Iinuma K, et al. Among authors: takagi k. Cancers (Basel). 2023 Feb 2;15(3):947. doi: 10.3390/cancers15030947. Cancers (Basel). 2023. PMID: 36765903 Free PMC article.
Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer.
Kawase M, Takagi K, Kawada K, Ishida T, Tomioka M, Enomoto T, Fujimoto S, Taniguchi T, Ito H, Kameyama K, Yamada T, Kawase K, Kato D, Takai M, Iinuma K, Nakane K, Koie T. Kawase M, et al. Among authors: takagi k. Curr Oncol. 2022 Aug 1;29(8):5466-5474. doi: 10.3390/curroncol29080432. Curr Oncol. 2022. PMID: 36005170 Free PMC article.
Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.
Yamada T, Nakane K, Enomoto T, Tomioka M, Taniguchi T, Ishida T, Ozawa K, Takagi K, Ito H, Takeuchi S, Kawase M, Kawase K, Kato D, Takai M, Iinuma K, Yokoi S, Nakano M, Koie T. Yamada T, et al. Among authors: takagi k. Biomedicines. 2022 Sep 9;10(9):2243. doi: 10.3390/biomedicines10092243. Biomedicines. 2022. PMID: 36140344 Free PMC article.
Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.
Iinuma K, Kameyama K, Taniguchi T, Kawada K, Ishida T, Takagi K, Nagai S, Enomoto T, Tomioka M, Kawase M, Takeuchi S, Kato D, Takai M, Nakane K, Koie T. Iinuma K, et al. Among authors: takagi k. Cancers (Basel). 2022 Sep 21;14(19):4579. doi: 10.3390/cancers14194579. Cancers (Basel). 2022. PMID: 36230501 Free PMC article.
The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma.
Tomioka-Inagawa R, Nakane K, Enomoto T, Tomioka M, Taniguchi T, Ishida T, Ozawa K, Takagi K, Ito H, Takeuchi S, Kawase M, Kawase K, Kato D, Takai M, Iinuma K, Yokoi S, Nakano M, Koie T. Tomioka-Inagawa R, et al. Among authors: takagi k. Biomedicines. 2022 Jul 6;10(7):1609. doi: 10.3390/biomedicines10071609. Biomedicines. 2022. PMID: 35884914 Free PMC article.
26 results